ResMed (NYSE:RMD) Stock Gets Price Target Bump from KeyCorp

ResMed (NYSE:RMD) had its price target boosted by equities research analysts at KeyCorp from $267.00 to $277.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the medical equipment provider’s stock. KeyCorp‘s price target suggests a potential upside of 9.92% from the stock’s current price.

A number of other analysts have also weighed in on RMD. Jefferies Financial Group lowered their target price on ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a report on Friday, July 10th. Piper Sandler cut their price target on ResMed from $233.00 to $225.00 and set a “neutral” rating for the company in a research note on Friday, August 7th. Royal Bank Of Canada upgraded ResMed from a “sector perform” rating to an “outperform” rating and raised their price objective for the company from $244.00 to $262.00 in a report on Tuesday, September 15th. UBS Group reissued a “buy” rating and issued a $300.00 price target on shares of ResMed in a research note on Tuesday, July 21st. Finally, Needham & Company LLC restated a “hold” rating on shares of ResMed in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $246.31.

ResMed Stock Up 0.7%

Shares of RMD stock opened at $252.00 on Friday. ResMed has a 12 month low of $180.26 and a 12 month high of $277.67. The company has a current ratio of 3.10, a quick ratio of 2.42 and a debt-to-equity ratio of 0.06. The stock has a market cap of $35.44 billion, a P/E ratio of 24.16, a P/E/G ratio of 1.53 and a beta of 0.75. The company has a 50 day simple moving average of $231.83 and a two-hundred day simple moving average of $225.57.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.67 by $0.24. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.39 billion. During the same quarter in the prior year, the firm posted $2.55 EPS. ResMed’s quarterly revenue was up 5.9% compared to the same quarter last year. On average, research analysts expect that ResMed will post 12.11 earnings per share for the current year.

Insider Transactions at ResMed

In related news, General Counsel Michael Rider sold 400 shares of ResMed stock in a transaction on Friday, October 23rd. The shares were sold at an average price of $255.00, for a total value of $102,000.00. Following the transaction, the general counsel directly owned 12,318 shares in the company, valued at $3,141,090. This trade represents a 3.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Farrell sold 4,991 shares of the stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $226.33, for a total value of $1,129,613.03. Following the transaction, the chief executive officer directly owned 479,803 shares of the company’s stock, valued at approximately $108,593,812.99. This trade represents a 1.03% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 24,343 shares of company stock worth $5,396,098 over the last 90 days. 0.58% of the stock is currently owned by insiders.

Hedge Funds Weigh In On ResMed

Institutional investors have recently added to or reduced their stakes in the business. Mirae Asset Global Investments Co. Ltd. acquired a new stake in ResMed during the 3rd quarter worth approximately $7,916,000. Moss Adams Wealth Advisors LLC lifted its stake in ResMed by 3.1% during the third quarter. Moss Adams Wealth Advisors LLC now owns 3,477 shares of the medical equipment provider’s stock worth $769,000 after purchasing an additional 103 shares during the last quarter. MGO One Seven LLC acquired a new position in ResMed during the 3rd quarter valued at approximately $300,000. United Asset Strategies Inc. increased its holdings in shares of ResMed by 1.9% during the third quarter. United Asset Strategies Inc. now owns 16,934 shares of the medical equipment provider’s stock valued at $3,744,000 after purchasing an additional 318 shares during the period. Finally, Choreo LLC lifted its holdings in ResMed by 9.7% in the 3rd quarter. Choreo LLC now owns 4,297 shares of the medical equipment provider’s stock valued at $950,000 after acquiring an additional 381 shares during the last quarter. 54.98% of the stock is currently owned by institutional investors and hedge funds.

Key ResMed News

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q1 earnings and revenue beat estimates. ResMed reported fiscal Q1 2027 adjusted earnings of $2.91 per share, above the $2.67 analyst consensus and up from $2.55 a year earlier. Revenue rose 5.9% year over year to $1.41 billion, exceeding the $1.39 billion estimate. The company also reported a 26.94% net margin and 25.58% return on equity, reinforcing the earnings-driven support for RMD. ResMed Beats Q1 Earnings and Revenue Estimates
• Positive Sentiment: Dividend maintained at $0.66 per share. ResMed declared a quarterly dividend payable December 17 to shareholders of record November 12. The $2.64 annualized payout represents an approximately 1.0% yield and adds to shareholder returns, although the ex-dividend date may produce normal short-term trading adjustments. ResMed Posts Strong Q1 Results and Shareholder Returns
• Neutral Sentiment: Investors will focus on the outlook and valuation. Earnings-call coverage highlighted the quarterly performance, while ResMed’s shares trade near the upper end of their 52-week range. With a reported price-to-earnings ratio of about 24, continued appreciation may depend on sustaining growth beyond the current 6% revenue expansion. ResMed Q1 2027 Earnings Call Transcript

ResMed Company Profile

ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.

ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.